Interleukin-11 (IL-11), which belongs to a class of IL6-type cytokines, plays an important role in inflammation, motility and invasion in cancer. The ras mutation is frequently found in human cancer, but little is known regarding the transcriptional activation of the IL-11 gene by the Ras signal pathway in tumour cells. In this study, we investigated the role of Ras in the regulation of IL-11 using two different cell model systems: mouse NIH3T3 cells over-expressing oncogenic Ras with a tet-on system and Capan-1 human pancreatic carcinoma cells harbouring a K-ras mutation. We found that IL-11 expression was up-regulated at the transcriptional level by oncogenic Ras. Activation of the AP-1 response element, located between -153 and -30 in the 5′-regulatory region of the IL-11 gene, was necessary for oncogenic Ras-induced IL-11 promoter activation. AP-1 proteins, including Fra-1 and Fra-2, were up-regulated through the Raf/MEK and phosphatidylinositol 3-kinase (PI3K)/Akt pathways by oncogenic Ras. Knockdown of Fra-1 by siRNA in NIH3T3 or Capan-1 cells strongly attenuated oncogenic Ras-induced IL-11 expression. Additionally, inhibition of JNK, p38 and Stat3 abrogated oncogenic Ras-induced IL-11 expression. These results suggest that both the PI3K and Raf pathways are necessary for the expression of IL-11 in oncogenic Ras-mutated cells, and that JNK, p38 and Stat3 also contribute to oncogenic Ras-induced IL-11 expression.
Introduction
Interleukin-11 (IL-11), a cytokine, is a member of the IL6-type cytokines, which include IL6, leukaemia inhibitory factor and oncostatin M (OSM). IL-11 binds to a specific receptor (IL-11Rα) to activate Janus kinase and signal transducer and activator of transcription (STAT) via the transmembrane signal transducer gp130 (1) . IL-11 is expressed in diverse cell types such as bone marrow-derived stromal cells (2) , lung fibroblasts (3) and chondrocytes (4) . It plays important roles in haematopoiesis, adipogenesis, neuronal differentiation and bone metabolism (5) .
Elevated levels of IL-11 and its receptor IL-11Rα have been observed in some cancers, including primary ovarian carcinoma (6) , prostate carcinoma (7), breast cancer (8) , colorectal carcinoma (9), gastric carcinoma (10, 11) and endometrial carcinoma (12) , suggesting that the autocrine loop of IL-11 may have an important function in the progression of tumourigenesis. Elevated expression levels of IL-11 and IL-11Rα correlate with cell proliferation, invasiveness, metastatic potential and poor prognosis (8) (9) (10) . Additionally, increased IL-11 production has been reported to play a crucial role in TGF-β-induced bone metastasis of breast cancer cells (13) . In cancer cells, IL-11 expression is regulated by several transcription factors, including Stat3 and AP-1 (14, 15) . AP-1 proteins are composed of homo-or hetero-dimers of Jun (c-Jun, JunB and JunD) or Fos (c-Fos, Fra-1, Fra-2 and FosB) family members, and most AP-1 proteins may be associated with oncogene-induced transformation and up-regulated by oncogenic Ras (16) (17) (18) . Stat3 activation is frequently observed in many human cancers and is associated with inflammation-associated gastric tumourigenesis (14) . However, the regulatory mechanisms underlying IL-11 gene expression in cancer cells remain unclear.
The small GTPase family of Ras proteins (H-Ras, K-Ras and N-Ras) initiates the activation of diverse cytoplasmic signalling networks that are involved in the regulation of cell growth, differentiation, survival and apoptosis in diverse cell types (19, 20) . Ras is one of the most frequently mutated oncogenes in human cancer (20, 21) . Mutational activation of Ras results in aberrant activation of downstream effectors, including the Raf, PI3K, PLCε and RalGDS pathways, leading to deregulated expression of genes essential for the promotion of malignant transformation (19, 20) . The interaction between tumour cells and the surrounding tissue environment such as stromal fibroblasts and infiltrating immune cells appears to play a key role in cancer development (22) . Aberrant activation of Ras signalling also promotes the interaction between tumour cells and their associated tissue microenvironments through the production of pro-inflammatory chemokines and cytokines such as IL8 (23, 24) , CXCL1/2/5 (24), IL10 and IL6 (25) . A previous study using oligonucleotide microarrays has reported that forced expression of oncogenic Ras up-regulates diverse chemokines and cytokines, including IL-11, in human ovarian epithelial cells (26) . However, little is known regarding the molecular mechanisms by which the Ras signalling pathway mediates the transcriptional activation of the IL-11 gene.
In this study, we analysed the functional role of oncogenic Ras in the production of IL-11 using an NIH3T3 cell model that can conditionally express oncogenic H-Ras with the addition of doxycycline. We demonstrate that oncogenic Ras up-regulates AP-1 proteins, including Fra-1 and Fra-2, through Raf and phosphatidylinositol 3-kinase (PI3K) signalling, to enhance IL-11 promoter activity. We also show that the Raf and PI3K pathways are required for IL-11 expression in serum-exposed Capan-1 cells harbouring the K-ras mutation. Additionally, we further show that the knockdown of IL-11 expression using small interfering RNA (siRNA) in Capan-1 cells attenuated the invasive capability of Capan-1 cells. These observations suggest a novel mechanism by which oncogenic Ras-mutated tumour cells can trigger tumour invasion through the production of IL-11.
Materials and methods
Cells and cell culture NIH3T3 cells and NIH3T3tet-on/H-RasG12R cells conditionally expressing oncogenic Ras by the addition of doxycycline and NIH3T3 cells overexpressing Ras effector mutants have been described elsewhere (27) . Human embryonic kidney HEK293, bladder carcinoma T24, pancreatic adenocarcinoma Capan-1, fibrosarcoma HT1080 and colon carcinoma HT29 cell lines were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum (Hyclone).
were donated by Julian Downward (Cancer Research UK London Research Institute, London, UK), and dn-MEK1 (pCGN1/MEK DN), dn-RasN17 (pSV/H-RasN17), dn-p38 (pcDNA3/flag-p38 inactivate) and dn-JNK1 (pSR2/ HA-JNK DN) were provided by Dr D. S. Min (Department of Molecular Biology, College of Natural Science, Pusan National University, Korea). Expression plasmid for dn-Stat3 (pEF/flag-mStat3Y705F) was obtained from RIKEN BioResource Center (Ibaraki, Japan).
Reverse transcription-PCR and quantitative real-time-PCR
Total RNA was extracted using a TRIzol RNA extraction kit (Invitrogen). First-strand cDNA was synthesised from 500 ng of total RNA using an iScript cDNA synthesis kit (Bio-Rad). PCR conditions were as follows: hold for 5 min at 94°C, followed by 30 cycles consisting of denaturation at 94°C (30 s), annealing at 55°C (30 s) and elongation at 72°C (1 min). The amplified products were subjected to electrophoresis in a 1% agarose gel. Quantitative real-time PCR (QRT-PCR) was performed on an iCycler iQ™ system (Bio-Rad) using a TaqMan-iQ™ Supermix kit (Bio-Rad) according to the manufacturer's recommendation. The expression values were normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA (∆Ct) by subtracting the cycle threshold value of GAPDH mRNA from the Ct value of the experimental sample using the software program provided by the manufacturer (28) . The RT-PCR primers and TaqMan™ fluorogenic probes were designed by Metabion International (Martinsried, Germany). Mouse IL-11 RT-PCR-forward, 5′-ACTCGGGACTGAAAACCACC-3′; reverse, 5′-AGACCCTGAAGAGCAGGGAA-3′; mouse β-actin RT-PCRforward, 5′-GAAGTACCCCATTGAACACG-3′; reverse, 5′-CCCAGATCAT GTTTGAGACC-3′; human IL-11 RT-PCR-forward, 5′-ACTGCTGCTGCT GAAGACTCGGCTGTG-3′; reverse, 5′-ACAGACTTCTGCCCTGGCTCTTC CCCAT-3′; human GAPDH RT-PCR-forward, 5′-ACCCACTCCTCCA CCTTTG-3′; reverse, 5′-CCCAGCAAGAGCACAAGAG-3′; mouse IL-11 Q-PCR-forward, 5′-GCCTGTGGGGACATGAACTG-3′; reverse, 5′-AGGGGC AACGACTCTATCTGG-3′; TaqMan fluorogenic probe-5′-FAM-CAGCACCA CCAGGACCAGGCGA-BHQ-1-3′; mouse GAPDH QRT-PCR-forward, 5′-CCAAGGAGTAAGAAACCCTGGAC-3′; reverse, 5′-GGGCCGAGTTGGG ATAGGG-3′; TaqMan fluorogenic probe-5′-Yakima Yellow™-ACCCCAGCA AGGACACTGAGCAAG-BHQ-1-3′; human IL-11 QRT-PCR™ forward, 5′-GGTTAAGCAACATGGTGCATCTG-3′; reverse, 5′-TTTCTATATCCCA AGCAAGCCTCTC-3′; and TaqMan fluorogenic probe-5′-FAM-TTTCTAT ATCCCAAGCAAGCCTCTC-BHQ-1-3′.
Immunohistochemistry
Paraffin wax-embedded tissue sections were dewaxed using standard procedures. Immunohistochemical staining was performed using an antibody against IL-11, as described previously (12) . The biospecimens for this study were provided by the Chonnam National University Hwasun Hospital National Biobank of Korea, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. All samples from the National Biobank of Korea were obtained with informed consent under Institutional Review Board-approved protocols.
Transwell invasion assay
The Transwell migration assay was performed utilising a CytoSelect™ 24-well cell migration and invasion assay kit (8 µm pore size; Cell Biolabs, Inc). The assay was performed exactly as specified by the manufacturer's protocol. In brief, Capan-1/Cont and Capan-1/siIL-11 cells were serum starved for 24 h, and a cell suspension containing 5 × 10 5 cells/ml in 20% serum or 10 ng/ml of IL-11 was prepared and seeded in the upper chamber onto a polycarbonate filter coated with Matrigel-based basement membrane proteins. The cells were allowed to invade for 24 h. Cells on the top of the filters were removed with cotton swabs, and cells that invaded the bottom of the filters were fixed, stained, extracted and quantified at 560 nm optical density (OD) according to the manufacturer's instructions.
Western blot analysis
Antibodies against IL-11 (1:500), Fra-1 (1:1000), Fra-2 (1:1000), c-Fos (1:500), c-Jun (1:1000) and GAPDH (1:500) were obtained from Santa Cruz Biotechnology and Pan-Ras (OP23; 1:250) was from Calbiochem. PhosphoErk1/2 (Thr202/Tyr204; 1:1000), phospho-JNK (1:500), phospho-p38 (1:250), phospho-Akt (Ser473; 1:1000), Stat3 (1:500) and phospho-Stat3 (Ser727; 1:500) were purchased from Cell Signalling Technology. Cells were lysed in a buffer consisting of 20 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (pH 7.2), 1% Triton X-100, 10% glycerol, 150 mM NaCl, 10 μg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride. The protein extracts (20 μg each) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The blots were incubated with the appropriate primary and secondary antibodies and developed using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
Construction and mutagenesis of the human IL-11 promoter reporter construct
A fragment of the human IL-11 gene spanning nucleotides -997 to +14 (transcription start site being numbered +1) was amplified from human genomic DNA (Promega) by PCR using the primers 5′-TGAGCTGAGATTGTGCCATTGA-3′ (forward; -997F) and 5′-CTGCTGCTCAGGGCACATG-3′ (reverse; +14R). The amplified PCR products were ligated into T&A vector (RBC Bioscience), digested with KpnI and BglII, and then subcloned into the luciferase reporter plasmid pGL4-basic (Promega), yielding pIL11-Luc(-997/+14). A series of deletion constructs was generated using pIL11-Luc(-997/+14) as a template. Forward primer sequences were 5′-TTTCTCTGCCTTTCCGTCCT-3′ (−399 to +14), 5′-CAGCCCCTCTCCGACCAC-3′ (-249 to +14), 5′-GCAGCCGCTCCG TCTGAATGG-3′ (-153 to +14) and 5′-TCCACACTCCCTCACTGCC-3′ (-30 to +14). One reverse primer, +14R, was used for all deletion constructs. The amplified PCR products were ligated into T&A vector and then ligated into the KpnI and BglII sites of pGL4-basic vector, yielding pIL11-Luc(−399/+14), pIL11-Luc(-249/+14), pIL11-Luc(-153/+14) and pIL11-Luc(-30/+14). Site-specific mutation of the AP-1 binding site within the IL-11 promoter was performed with a QuickChange site-directed mutagenesis system (Stratagene) using pIL11-Luc(-153/+14) as a template. The primer sequences used to generate point mutations for disruption of the AP-1 binding site were 5′-GGCAGGCAGGGAGGGCAAGTCAGGATGTGTCAG-3′ (forward) and 5′-GGCAGGCAGGGAGGGCAAGTCAGGATGTGTCAG-3′ (reverse) (mutated bases are underlined). All mutations were verified by DNA sequencing.
Transient transfection and promoter reporter assay
Cells were seeded in 12-well plates and transfected with 0.5 µg of the IL-11 promoter constructs using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer's instructions. Where indicated, mammalian expression vectors were also included. To monitor the transfection efficiency, 50 ng of pRL-null plasmid encoding Renilla luciferase were included in all samples. At 24 h post-transfection, the levels of firefly and Renilla luciferase activities were measured using a Dual-Glo™ Luciferase assay system (Promega), and luminescence was measured with a dual luminometer (Centro LB960; Berthold Tech). The firefly luciferase activity was normalised to the Renilla activity, and the relative amount of luciferase activity in the untreated cells was set to '1'.
Electrophoretic mobility shift assay
Synthetic deoxyoligonucleotides (4 pmol) corresponding to the AP-1 binding sequence (GGGAGGGTGAGTCAGGATG) within the IL-11 promoter were radioactively labelled by incubation with 10 units of T4 polynucleotide kinase, 5 µl of T4 polynucleotide kinase buffer and 20 µCi of [γ- 32 P]dATP (Amersham Biosciences) for 30 min at 37°C, followed by inactivation at 65°C for 10 min. For electrophoretic mobility shift assay (EMSA), 10 µg of nuclear extract were mixed with the binding buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 , 2.5 mM dithiothreitol, 2.5 mM ethylenediaminetetraacetic acid, 250 mM NaCl, 20% glycerol), with 1 µg of poly(dI-dC) (Amersham Biosciences) as a non-specific competitor. DNA-protein complexes were electrophoresed in non-denaturing 6% polyacrylamide gels and visualised by autoradiography.
Chromatin immunoprecipitation assay
NIH3T3tet-on/H-RasG12R cells cultured in the absence or presence of doxycycline (2 μg/ml) for 24 h were treated with 1% formaldehyde to cross-link the DNA, lysed and chromatin immunoprecipitated using a rabbit anti-Fra-1 antibody or normal rabbit IgG as described previously (29) . The precipitated DNA was analysed by standard RT-PCR methods. The PCR primers were as follows: 5′-CGTGAGCCCTGCAAGGCA-3′ (forward, -168/-151) and 5′-GGGCGGGCGGGGGGCAG-3′ (reverse, -77/-61).
Expression of siRNA Fra-1 shRNA plasmids (pLKO.1-puro/Fra1; clone ID: NM_005438.2-780s1c1 and NM_005438.2-302s1c1) were obtained from Sigma-Aldrich. To generate the IL-11 shRNA expression plasmid, we used siRNA Target Finder™, a Web-based algorithm maintained by Ambion. The sequence corresponding to nucleotides +1842/+1862 (5′-AAGCAACATGGTGCATCTGTG-3′) in the 3′-untranslated region of the IL-11 gene was selected and subcloned into pSilencer 2.1-U6 siRNA expression vector (Ambion) according to the manufacturer's protocol, yielding pSilencer/siIL-11. For the transient expression of Fra-1 siRNA, Capan-1 cells were transfected with pSilencer/Cont or pSilencer/siIL-11 using Lipofectamine 2000. For the generation of cells stably expressing siRNA, Capan-1 cells were transfected with pLKO.1-puro/ Cont (for scrambled control) or pLKO.1-puro/siFra1 (for Fra-1 siRNA), or pSilencer/Cont (for scrambled control) or pSilencer/siIL-11 (for IL-11 siRNA) using Nucleofactor (AMAXA, Inc). Stable transfectants were selected with 20 μg/ml puromycin (for Fra-1 siRNA) or 400 μg/ml G418 (for IL-11 siRNA)
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2 days after transfection. After 2 weeks, the silencing of Fra-1 or IL-11 expression was verified by western blotting or QRT-PCR.
Statistical analysis
Each experiment was performed at least three times. The data are plotted as means ± SD. Statistical analysis was performed using Student's t-test for twotailed unpaired comparisons with the Microsoft Excel 2007 software. A P value of <0.05 was considered to indicate statistical significance.
Results

Over-expression of IL-11 in cancer cells containing a Ras mutation
Elevated IL-11 expression is frequently observed in diverse cancer types, including ovarian, prostate, breast, colorectal, gastric and endometrial carcinomas (6) (7) (8) (9) (10) (11) (12) . We further examined steady-state IL-11 expression in several human tumour cells harbouring the oncogenic ras mutation. RT-PCR analysis showed that T24 bladder cancer (H-ras mutation), Capan-1 pancreatic adenocarcinoma (K-ras mutation) and HT1080 fibrosarcoma (N-ras mutation) cells highly expressed IL-11, yet little or no expression was observed in HEK293 human embryonic kidney cells or HT29 colon carcinoma cells containing wild-type Ras ( Figure 1A ). In contrast, IL-11 receptor (IL-11Rα) expression was detected in all cell lines tested. Capan-1 pancreatic cancer cells exhibited relatively high IL-11 expression. QRT-PCR analysis confirmed the expression of IL-11 mRNA in these cancer cells ( Figure 1B ). The K-ras mutation is found in 70-90% of pancreatic cancer cases (21, 30) . The activating mutations in the K-ras gene occur early in the development of pancreatic neoplasia, before an invasive cancer develops, suggesting that aberrant activation of Ras signalling initiates and promotes pancreatic cancer growth (31) . Immunohistochemical staining showed that glandular epithelial cells in tissue sections of various grades of pancreatic adenocarcinoma displayed strong immunoreactivity to IL-11 antibody, whereas the signal was weak in normal pancreatic ducts and acini ( Figure 1C ),
Contribution of IL-11 to tumour cell invasion activity
IL-11 has been shown to activate the invasion of cancer cells (10, (32) (33) (34) . To evaluate the significance of the invasive capability of IL-11 in Capan-1 cells harbouring the oncogenic K-ras mutation, we generated stable transfectants expressing IL-11 siRNA (Capan-1/siIL-11). Western blot analysis showed that IL-11 expression and Stat3 phosphorylation were increased by serum stimulation after 24 h, which was attenuated by knocking out IL-11 ( Figure 1D ). The knockdown of IL-11 mRNA expression following serum treatment was also evaluated by QRT-PCR analysis ( Figure 1E ). We also found that serum-induced elevation of MMP-2 and MMP-9 mRNAs in Capan-1/ siIL-11 cells was strongly attenuated compared with the elevation in scrambled siRNA-transfected cells (Capan-1/siCT). To address the functional consequences of IL-11 silencing on the invasive capability of Capan-1 cells, we performed a transwell invasion assay. Compared with Capan-1/siCT cells, invasive migration of Capan-1/siIL-11 cells present on the bottom side of the basement membrane-coated filter decreased by ~50% ( Figure 1F ). These results suggest that IL-11 may contribute to tumour development in an autocrine fashion through, at least in part, the activation of the invasive capability of ras-mutated human pancreatic cancer cells.
Role of oncogenic Ras in IL-11 expression in NIH3T3 fibroblasts
To investigate whether oncogenic Ras regulates IL-11 gene expression, we used the NIH3T3tet-on/H-RasG12R cell system that conditionally expresses oncogenic H-Ras under a tetracycline-responsive promoter (27) . In this cell model, the expression of H-RasG12R protein and the activation of its downstream effectors, Erk1/2 and Akt, were detectable 12 h after adding doxycycline (Figure 2A) . Phosphorylation of Stat3, Akt, Erk1/2 and JNK gradually increased up to 24 h, whereas p38 phosphorylation peaked within 12 h and declined thereafter. Under these conditions, we observed an increase in IL-11 expression using QRT-PCR ( Figure 2B ) and western blot analysis ( Figure 2C ). These data demonstrate that up-regulation of IL-11 expression coincided with oncogenic Ras expression in NIH3T3 cells.
AP-1 response element is necessary for Ras-induced IL-11 promoter activity
To identify the Ras-responsive elements within the IL-11 promoter, a series of 5′-deletion constructs of the human IL-11 gene was generated and transfected into NIH3T3 cells. Transient transfection of H-RasV12 led to the induction of reporter activity in the-997/+14, -399/+14 and -249/+14 constructs ( Figure 2D ). Deletion from -249 to -153 resulted in high basal activity (4.1-fold that of the parent reporter) and a drastic increase in Ras responsiveness (5.3-fold that of the parent reporter), suggesting that negative regulatory element(s) may be located between nts -249 and -153. Further removal to position -30 resulted in the complete loss of Ras-induced reporter activity, implying that an essential Ras-responsive element is located between -153 and -30 of the IL-11 promoter.
Two AP-1 binding sites are reported to be located between -153 and -30 (35, 36) . These AP-1 sites are critical for IL-11 transcription in diverse cell types (15, 37, 38) . As AP-1 is a well-known target of the Ras signalling pathway (16, 17) , we investigated the possible contribution of AP-1 response elements in Ras-induced IL-11 transcription. A core sequence of the AP-1 binding site on the promoter (-120/-102) was disrupted within the context of the -153/+14 construct by sitedirected mutagenesis ( Figure 2E ). An AP-1 site mutation (mtAP-1; gtgagtca ≤ gAACgCca) led to a drastic decrease in RasV12-mediated reporter activity. These results indicate that AP-1 elements within the IL-11 promoter are necessary for maximal activation of IL-11 gene transcription by the Ras signalling pathway.
Oncogenic Ras-activated AP-1 proteins stimulate the IL-11 promoter AP-1 is composed of two proteins belonging to the Jun (c-Jun, JunB or JunD) or Fos (c-Fos, Fra-1, Fra-2 or FosB) family. We next analysed the expression of the different AP-1 components. In agreement with previous studies (16) (17) (18) , Fra-1 and c-Jun expression increased with the conditional expression of oncogenic Ras, whereas Fra-2 mobility was shifted, probably due to an increase in Erk-dependent phosphorylation in NIH3T3 cells ( Figure 3A) . Similar results were obtained in human Capan-1 pancreatic cancer cells. The levels of Fra-1 and Fra-2 proteins increased after the addition of serum, whereas c-Jun expression was little affected, probably owing to saturation by constitutively activated oncogenic Ras ( Figure 3B ).
To determine whether AP-1 proteins trans-activate the IL-11 promoter, NIH3T3 cells were co-transfected with the -153/+14 construct and AP-1 protein expression plasmids. The ectopic expression of Fra-1 or c-Jun alone activated reporter activity, and the combined transfection additively enhanced reporter activity ( Figure 3C ). We next determined whether AP-1 proteins bind to the IL-11 promoter in response to oncogenic Ras activation. Nuclear extracts from NIH3T3tet-on/H-RasG12R cells treated with doxycycline were prepared and incubated with the 32 P-labeled AP-1 binding sequences spanning -120/-102 within the IL-11 promoter. EMSA analysis showed that the DNA-protein complex increased with the conditional expression of oncogenic Ras, which was then displaced upon the addition of unlabelled oligonucleotides (cold competitor) ( Figure 3D ). The DNA-protein complex was partially supershifted with the addition of an antibody against Fra-1 or c-Jun, suggesting that multiple components of AP-1 proteins could bind to the AP-1 consensus motifs within the IL-11 promoter. To determine whether AP-1 proteins bound to the AP-1 consensus motif in vivo, we performed a chromatin immunoprecipitation assay. NIH3T3tet-on/HRasG12R cells were cultured in the absence or presence of doxycycline. After 24 h, cells were cross-linked and immunoprecipitation was performed with a rabbit anti-Fra-1 antibody or normal rabbit IgG. The resulting immunoprecipitates were analysed by PCR assays using primers flanking the AP-1 binding sequences (-168 to -61) of the IL-11 promoter. A noticeable increase in the intensity of the DNA band was observed for rabbit anti-Fra-1 antibody but not for the normal rabbit IgG (Figure 3E ), indicating that a physical interaction between Fra-1 and the IL-11 promoter occurs in vivo in response to activation of oncogenic Ras. Thus, oncogenic Ras stimulated the AP-1 response element within the IL-11 promoter through up-regulation of AP-1 proteins. Values were normalised to GAPDH mRNA levels. The data are the means ± SD of three independent experiments performed in triplicate. *P < 0.05, **P < 0.001. (F) A cell suspension in serumfree medium was seeded onto a matrigel-coated filter and then either stimulated or not stimulated with 20% serum. The cells were allowed to invade for 24 h. After fixing with 6% glutaraldehyde, invasive cells on the bottom of the insert were stained with 0.1% crystal violet (left photographs) and extracted for OD measurement at 560 nm in a plate reader (right graph). The data are the means ± SD of three independent experiments performed in triplicate. **P < 0.01.
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Silencing of Fra-1 attenuates IL-11 expression
To further address whether AP-1 expression was required for oncogenic Ras-mediated IL-11 expression, an RNA interference approach was employed. Knockdown of Fra-1 expression due to transient expression of siRNA directed against Fra-1 was confirmed by western blot analysis in NIH3T3 cells ( Figure 4A ). Transient silencing of Fra-1 siRNA significantly attenuated the ability of oncogenic Ras to induce IL-11 promoter activity, as compared with transfection of scrambled control siRNA ( Figure 4B ). To address whether Ras signalling is involved in IL-11 expression in Capan-1 pancreatic cancer cells, cells were co-transfected with the -153/+14 IL-11 promoter construct and an expression plasmid for dn-Ras. Serum-induced IL-11 promoter reporter activities were significantly blocked (n = 9, P < 0.01) by transfection with H-RasN17 ( Figure 4C ), suggesting that Ras signalling contributes to IL-11 transcription in Capan-1 cells. We next established Capan-1 transfectants stably expressing scrambled siRNA (Capan-1/siCT) or Fra-1 siRNA (Capan-1/siFra-1). The knockdown of endogenous Fra-1 expression was verified using western blot analysis ( Figure 4D) . A QRT-PCR analysis demonstrated a 7.2-fold increase in the level of IL-11 mRNA transcripts in Capan-1/siCT cells but only a 2.3-fold increase in Capan-1/siFra-1 cells following serum treatment, as compared with basal levels ( Figure 4E ). These data suggest that AP-1 proteins play an important role in the regulation of IL-11 transcription by oncogenic Ras.
Oncogenic Ras activates AP-1 through the Raf and PI3K pathways in NIH3T3 fibroblasts
The activation of Ras leads to the stimulation of the various effector pathways, including the Raf, PI3K, PLCε and RalGDS pathways (19, 20) . To determine the pathways downstream of Ras that are involved in the induction of IL-11 expression, we used NIH3T3 transfectants stably expressing site-specific Ras effector mutants (27) . The over-expression of RasV12, RasV12C40 (preferential activation of PI3K), RasV12E38 (preferential activation of Raf) or RasV12A38 (totally inactive) ( Figure 5A ) enhanced IL-11 mRNA expression compared with expression in control cells transfected with empty vector ( Figure 5B ). To evaluate the role of these pathways, we utilised pharmacological inhibitors in NIH3T3tet-on/H-RasG12R cells. Treatment with either the PI3K inhibitor LY294002, the Akt inhibitor API-2 or the MEK inhibitor U0126 abrogated Fra-1 accumulation and Fra-2 phosphorylation induced by oncogenic Ras ( Figure 5C ). Furthermore, oncogenic Ras-induced IL-11 mRNA expression was significantly reduced in the presence of the LY294002, API-2 or U0126, as revealed by QRT-PCR ( Figure 5D ). In contrast, the platelet-derived growth factor receptor kinase inhibitor Tyrphostin AG1295 had no significant effect on doxycycline-induced IL-11 mRNA accumulation, suggesting that upstream growth factor receptor tyrosine kinase activities did not significantly influence oncogenic Ras-induced IL-11 expression. In addition, consistent with a previous report on intestinal myofibroblasts stimulated by IL1β and TGFβ1 (38), we found that the p38 kinase inhibitor SB203580, or the JNK inhibitor SP600125, significantly abrogated oncogenic Ras-induced IL-11 mRNA expression. These data suggest that in addition to the PI3K/Akt and Raf/ Erk pathways, other JNK and p38 MAPK pathways may be required for maximal activation of oncogenic Ras-induced IL-11 expression. Since Stat3 is important for gp130 receptor-mediated expression of multiple cytokines, including IL-11, and Stat3 phosphorylation was slightly increased by oncogenic Ras (Figure 2A) , we also tested the role of Stat3 in oncogenic Ras-induced IL-11 expression. We found that the Stat3 inhibitor S3I-201 weakly albeit significantly reduced IL-11 mRNA accumulation, suggesting that transcriptional activation Log-phase cultured NIH3T3tet-on/H-RasG12R cells were harvested at different time points after the addition of doxycycline (2 μg/ml). Expression level of pan-Ras or phosphorylation status of Akt, Erk1/2, JNK, p38 and Stat3 was determined by western blotting. GAPDH was used as an internal control. (B and C) Log-phase cultured NIH3T3tet-on/H-RasG12R cells were harvested at different time points after the addition of doxycycline (Doxy; 2 μg/ml). IL-11 expression was determined using QRT-PCR (B) and western blotting (C). *P < 0.05, **P < 0.01. GAPDH was used as an internal control. (D and E) NIH3T3 cells were transfected with 0.2 µg of a series of 5′-deletion constructs (D), or wild-type (WT) or the AP-1 site-specific mutant (mtAP-1) of the pIL11-Luc(-153/+14) (E) of human IL-11 promoter reporter plasmids. After 24 h, the cells were treated with doxycycline (2 μg/ml) for an additional 24 h and assayed for luciferase activity. Schematics of the reporter constructs used in the transfection assay show the serial deletions or targeted mutations of the conserved AP-1 binding motif. The data are the means ± SD of three independent experiments performed in triplicate. ns, not significant. *P < 0.05, **P < 0.01 compared with the group untreated with doxycycline (-Doxy).
Oncogenic Ras expression of IL-11
of Stat3 is involved in oncogenic Ras-induced IL-11 expression. These data suggest that oncogenic Ras activates AP-1 through the Raf/MEK and PI3K/Akt signalling pathways to stimulate the transcription of the IL-11 gene and that other signalling pathways, such as p38, JNK and Stat3, also participated in oncogenic Ras induction of IL-11.
Both the Raf and PI3K pathways are necessary for maximal induction of IL-11 expression
In Capan-1 cells, phosphorylation levels of Erk, JNK and Stat3 were constitutively elevated and refractory to serum stimulation, probably due to excess activation by mutated K-Ras; however, serum stimulation was necessary for activation of Akt and p38 kinase ( Figure 6A ). To further determine the involvement of the Raf and PI3K pathways in Capan-1 cells, we examined the effect of inhibition of these pathways on the activation of AP-1. Pre-treatment with U0126 efficiently reduced Erk1/2 phosphorylation and inhibited serum-induced Fra-1 and Fra-2 activation, whereas LY294002 blocked serum-induced Fra-1 activation, but had no effect on Fra-2 ( Figure 6B) . A promoter reporter assay showed that basal luciferase activity of the -153/+14 construct was significantly reduced by LY294002, API-2, U0126, P-labeled oligonucleotide probe containing the AP-1 binding sequence in the absence or presence of cold competitor or antibody to Fra-1 or c-Jun. Arrow, DNA-protein complex; Arrowhead, supershifted DNA-protein complex. (E) NIH3T3tet-on/HRasG12R cells were treated with doxycycline (2 μg/ml) for 24 h, and chromatin immunoprecipitated with rabbit anti-Fra-1 antibody or with normal rabbit IgG. The precipitated DNA was subjected to PCR with primers specific to the IL-11 promoter. An aliquot of genomic DNA was used as a positive control (Input). The schematic representation at bottom shows the locations of the AP-1 binding sites and PCR primers in the IL-11 promoter.
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SB203580 and SP600125, but not by Tyrphostin AG1295 (Figure 6C ). Furthermore, transient transfection with an expression plasmid for dn-Akt, dn-MEK1, dn-p38 or dn-JNK1 significantly abrogated basal promoter reporter activity, whereas da-PI3K (p110-CAAX) alone was sufficient to enhance reporter activity ( Figure 6D ). Although AP-1 components were differentially regulated based on the cellular contexts, our results demonstrate that both the Raf and PI3K signalling pathways are necessary for maximal induction of oncogenic Rasinduced IL-11 expression through activation of AP-1.
Discussion
IL-11 is produced at high levels in some aggressive tumours, including ovarian carcinoma (6), prostate carcinoma (7), breast cancer (8), colorectal carcinoma (9), gastric carcinoma (10) and endometrial carcinoma (12) , indicating a potential role of IL-11 in tumour development. Although numerous studies have demonstrated a role for oncogenic Ras in the up-regulation of many cytokines and chemokines in diverse cell types (23, 24, 39) , little information is available as to whether oncogenic Ras stimulates IL-11 gene expression. In this study, we sought to determine the role of oncogenic Ras in the regulation of IL-11 gene transcription using NIH3T3 fibroblasts that conditionally express oncogenic H-Ras and Capan-1 cells that harbour activating mutations in the K-ras gene. Our analysis revealed an essential function of the AP-1 response element within the IL-11 promoter in Ras-induced IL-11 transcription. We found that both the Raf and PI3K pathways are necessary for oncogenic Ras-induced IL-11 expression through activation of AP-1 components. The conditional expression of oncogenic H-Ras in NIH3T3 cells demonstrated that the activation of the Ras signalling pathway stimulates transcriptional activity of the IL-11 gene, as revealed by northern blot, real-time PCR and western blot analyses. In an effort to understand the molecular mechanism by which the IL-11 gene is regulated by oncogenic Ras, we identified the participating cis-acting response elements within the IL-11 gene promoter. Using serial deletion and site-directed mutagenesis, we found that the promoter region spanning positions −153 to -30 was indispensable for Ras-triggered IL-11 promoter activity in NIH3T3 cells. Two AP-1 sites that are essential for TGF-β1-induced IL-11 transcriptional activation have been reported to be located between -100 and -82 within the IL-11 promoter (15) . Using progressive deletions of the IL-11 promoter and site-directed mutation of the AP-1 binding site (tgagtca → aacgcca), we also identified a crucial role for an AP-1 binding element located between -120 and -102 within the IL-11 promoter. Although AP-1 is regulated by Ras signalling, no information is available about the direct involvement of AP-1 in Ras-induced IL-11 expression in cancer cells. Here, we demonstrated that an AP-1 binding site mutation led to a loss of ~60% of the oncogenic Ras-induced IL-11 promoter . Approximately 24 h after transfection, the cells were serum starved for 24 h prior to incubation with 20% serum for 12 h, and then assayed for luciferase activity. The data are the mean ± SD of three independent experiments performed in triplicate. **P < 0.01. (D) Stable Capan-1 transfectants expressing scrambled siRNA (siCT) or Fra-1 siRNA (siFra-1) were serum starved for 24 h and then stimulated with 20% serum for 1 h, and western blot analysis was performed using antibody to Fra-1. GAPDH was used as an internal control. (E) Serum-starved Capan-1/siCT and Capan-1/ siFra-1 cells were stimulated with 20% serum for 12 h. Total RNA was prepared, and IL-11 mRNA expression was measured using QRT-PCR. The data are the mean ± SD of three independent experiments performed in triplicate. **P < 0.01.
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reporter activity. AP-1 proteins are composed of two proteins belonging to the Jun (c-Jun, JunB and JunD) or Fos (c-Fos, Fra-1, Fra-2 and FosB) family. Homo-or heterodimerisation of AP-1 components is a key regulatory mechanism controlling DNA-binding specificity of the AP-1 complex. Most AP-1 proteins may be associated with oncogeneinduced transformation in a tissue-specific way (40) . Among them, Fra-1 is the most abundant in tumours expressing oncogenic Ras and is a crucial mediator for Ras-induced transformation (16) (17) (18) . We also observed that the Fra-1 level was strongly increased by conditional expression of oncogenic Ras in NIH3T3 cells. Moreover, the forced expression of Fra-1 in wild-type NIH3T3 cells enhanced IL-11 promoter activity. We further showed that Fra-1 is associated with the AP-1 response element within the IL-11 promoter, using EMSA analysis. These results demonstrate that the activation of an AP-1 cis-acting response element is important for oncogenic Ras-induced activation of the IL-11 gene. This fits well with the results seen in serum-starved Capan-1 pancreatic carcinoma cells upon exposure to serum. Another option for showing the importance of AP-1 in regulating IL-11 gene transcription in Capan-1 cells is the use of RNAi technology. We found that Fra-1-specific siRNA introduced into Capan-1 cells strongly attenuated serum-induced IL-11 transcription. Thus, although the roles of individual AP-1 components were not fully identified in this study, we suggest that Fra-1 activation is essential for oncogenic Ras activation of the IL-11 promoter. Oncogenic Ras leads to the stimulation of various effector pathways, including the Raf, Ral and PI3K pathways (19, 20) . Site-specific Ras mutants can distinguish among the downstream effector pathways of Ras: RasV12G37 preferentially activates Ral GDS, RasV12E38 preferentially activates Raf and RasV12C40 preferentially activates PI3K, whereas RasV12A38 activates none of these molecules (41) (42) (43) . Our analysis of the Ras effector pathways in NIH3T3 cells over-expressing site-specific Ras mutants showed that preferential activation of either the Raf or PI3K pathway is sufficient to mediate oncogenic Ras-induced IL-11 expression. Furthermore, inhibition of one pathway alone (either PI3K, Akt or MEK1) considerably abrogated oncogenic Ras-induced AP-1 activation and IL-11 expression.
These results suggest that both PI3K and Raf pathways are necessary for maximal induction of IL-11 by oncogenic Ras in NIH3T3 cells. In K-Ras-mutated Capan-1 cells, inhibition of either the Raf/ MEK1 or PI3K/Akt pathway also inhibited AP-1 and IL-11 expression. A transient transfection study in Capan-1 cells showed that IL-11 promoter activity of the -154/+14 construct was significantly inhibited by transfection with dn-Akt or dn-MEK1, whereas da-PI3K (p110-CAAX) enhanced IL-11 promoter reporter activity. The inducible H-Ras model used in NIH3T3 cells exhibited strong phosphorylation of both Akt and Erk1/2 associated with oncogenic Ras-induced IL-11 expression. In contrast, Erk1/2 was constitutively activated in K-Ras-mutated Capan-1 cells, whereas Akt phosphorylation occurred only upon serum exposure and was associated with IL-11 expression in conjunction with active Erk1/2, suggesting that alternative downstream effectors are regulated in different Ras-mutated cells. Therefore, both the PI3K and Raf pathways are probably necessary for maximal expression of IL-11 by oncogenic Ras in NIH3T3 cells, in which Raf/MEK1 activity is critical, but further activation of PI3K/ Akt (e.g. serum stimulation) is required for maximal IL-11 expression in K-Ras-mutated Capan-1 cells.
We also found that phosphorylated levels of JNK and p38 were highly elevated due to oncogenic Ras expression in NIH3T3 cells. Ras has been reported to stimulate JNK and potentiate AP-1 transcriptional activity (44) , and p38 stabilises IL-11 mRNA at the posttranscriptional level (38) . To address the possible involvement of JNK and p38 MAPKs, we analysed the effect of chemical inhibitors on doxycycline-induced IL-11 mRNA expression using QRT-PCR. We found that inhibition of JNK or p38 significantly reduced the accumulation of IL-11 mRNA. Thus, we suggest that in addition to the PI3K/Akt and Raf/Erk pathways, other JNK and p38 MAPK pathways may be required for full activation of oncogenic Ras-induced IL-11 expression. We also observed that Stat3 phosphorylation gradually increased due to oncogenic Ras activation, and that inhibition of Stat3 significantly abrogated oncogenic Ras-induced accumulation of IL-11 mRNA. This suggests that Stat3 also participated in oncogenic Ras-induced IL-11 expression in NIH3T3 cells. Although we have no The data are the mean ± SD of three independent experiments performed in triplicate. ns, not significant. *P < 0.05, **P < 0.01.
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direct evidence at the present time, an increase in the level of Stat3 phosphorylation in oncogenic Ras-expressing cells may be mediated indirectly by IL-11 produced in an autocrine fashion, which may contribute to sustained expression of IL-11. It has been reported that both the Raf and PI3K signalling pathways are required for K-Ras-induced invasion of human pancreatic cells (45) . We also found that IL-11 knockdown by siRNA expression impaired the invasive capability of Capan-1 cells. Thus, it is tempting to speculate that enhanced IL-11 expression through PI3K and Raf signalling may contribute partially to Ras-induced oncogenesis.
In summary, this study demonstrated that the activation of Ras stimulated IL-11 gene transcription through an AP-1 cis-acting response element within the IL-11 promoter. Both the Raf/MEK and PI3K/Akt pathways mediated the Ras-induced activation of the AP-1 sites. Additionally, Ras-induced IL-11 expression may function as an autocrine loop and partially contribute to tumour development by stimulating the invasive capability of tumour cells. Our present findings contribute to the further understanding of an additional mechanism underlying Ras-mediated tumourigenesis. Total DNA amounts were normalised to the empty vector. At 24 h after transfection, the cells were collected and assayed for luciferase activity. The data are the mean ± SD of three independent experiments performed in triplicate. *P < 0.05, **P < 0.01.
Funding
Oncogenic Ras expression of IL-11
